Anup M Madan

US Patent:

20070248576, Oct 25, 2007

Filed:

Dec 22, 2006

Appl. No.:

11/644198

Inventors:

Robert Philibert - University Heights IA, US
Anup Madan - Bellevue WA, US

International Classification:

C12Q 1/68
C12N 5/00

US Classification:

424093700, 435325000, 435375000, 435006000, 536023100

Abstract:

Described herein is a CpG island in the 5′ region of the 5HTT gene that contains an alternative exon 1 and promoter for 5HTT. Methylation at this CpG island is associated with decreased levels of 5HTT mRNA, and this effect is evident when 5HTTLPR genotype is taken into account. Thus, this methylation status indicates 5HTT mRNA production, which serves as an indicator for the expression of the transporter and of a subject's vulnerability to diseases related to serotonergic activity. Accordingly, certain embodiments of the present invention provide diagnostic methods for determining whether a subject has, or is at risk for developing, a disease associated with serotonergic activity.

US Patent:

20070292880, Dec 20, 2007

Filed:

May 7, 2007

Appl. No.:

11/800629

Inventors:

Robert Philibert - University Heights IA, US
Anup Madan - Bellevue WA, US

International Classification:

C12Q 1/68
G01N 33/00

US Classification:

435006000, 436094000

Abstract:

The present invention provides screening kits, compositions, and diagnostic methods for determining whether a subject has a predisposition to, or likelihood of having, a substance use disorder or mental illness or syndrome by determining a nucleic acid expression profile from a biological sample from the subject, wherein a given profile indicates that the subject has a predisposition to a substance use disorder or mental illness or syndrome.

US Patent:

20110318735, Dec 29, 2011

Filed:

Apr 15, 2011

Appl. No.:

13/087993

Inventors:

Robert Philibert - Iowa City IA, US
Anup Madan - Iowa City IA, US

Assignee:

University of Iowa Research Foundation - Iowa City IA

International Classification:

C12Q 1/68

US Classification:

435 611

Abstract:

Described herein is a CpG island in the 5′ region of the 5HTT gene that contains an alternative exon 1 and promoter for 5HTT. Methylation at this CpG island is associated with decreased levels of 5HTT mRNA, and this effect is evident when 5HTTLPR genotype is taken into account. Thus, this methylation status indicates 5HTT mRNA production, which serves as an indicator for the expression of the transporter and of a subject's vulnerability to diseases related to serotonergic activity. Accordingly, certain embodiments of the present invention provide diagnostic methods for determining whether a subject has, or is at risk for developing, a disease associated with serotonergic activity.

US Patent:

20120108444, May 3, 2012

Filed:

Oct 28, 2011

Appl. No.:

13/284425

Inventors:

Robert Philibert - Iowa City IA, US
Anup Madan - Bellevue WA, US

International Classification:

C40B 20/08
C08G 83/00
C12Q 1/68
G01N 33/53
C07H 21/04
C40B 40/06

US Classification:

506 6, 536 2431, 506 16, 435 611, 436501, 525 542

Abstract:

The present invention provides screening kits, compositions, and diagnostic methods for determining whether a subject has a predisposition to, or likelihood of having, a substance use disorder by determining a nucleic acid methylation profile from a biological sample from the subject, wherein a given profile indicates that the subject has a predisposition to a substance use disorder.

US Patent:

20200071764, Mar 5, 2020

Filed:

Jul 12, 2019

Appl. No.:

16/510609

Inventors:

- Iowa City IA, US
Anup Madan - Bellevue WA, US

International Classification:

C12Q 1/6883
C12Q 1/6869

Abstract:

The present invention provides screening kits, compositions, and diagnostic methods for determining whether a subject has a predisposition to, or likelihood of having, a substance use disorder by determining a nucleic acid methylation profile from a biological sample from the subject, wherein a given profile indicates that the subject has a predisposition to a substance use disorder.

US Patent:

20200032343, Jan 30, 2020

Filed:

Sep 4, 2019

Appl. No.:

16/560210

Inventors:

- Iowa City IA, US
Anup Madan - Bellevue WA, US

International Classification:

C12Q 1/6883
C12Q 1/6869

Abstract:

The present invention provides screening kits, compositions, and diagnostic methods for determining whether a subject has a predisposition to, or likelihood of having, a substance use disorder by determining a nucleic acid methylation profile from a biological sample from the subject, wherein a given profile indicates that the subject has a predisposition to a substance use disorder.

US Patent:

20170306408, Oct 26, 2017

Filed:

May 15, 2017

Appl. No.:

15/594775

Inventors:

- Iowa City IA, US
Anup Madan - Bellevue WA, US

International Classification:

C12Q 1/68
C12Q 1/68

Abstract:

The present invention provides screening kits, compositions, and diagnostic methods for determining whether a subject has a predisposition to, or likelihood of having, a substance use disorder by determining a nucleic acid methylation profile from a biological sample from the subject, wherein a given profile indicates that the subject has a predisposition to a substance use disorder.

US Patent:

20160222452, Aug 4, 2016

Filed:

Feb 1, 2016

Appl. No.:

15/011830

Inventors:

Robert Philibert - Iowa City IA, US
Anup Madan - Bellevue WA, US

International Classification:

C12Q 1/68

Abstract:

The present invention provides screening kits, compositions, and diagnostic methods for determining whether a subject has a predisposition to, or likelihood of having, a substance use disorder by determining a nucleic acid methylation profile from a biological sample from the subject, wherein a given profile indicates that the subject has a predisposition to a substance use disorder.